Biomea Fusion (NASDAQ:BMEA) Upgraded by Wall Street Zen to Hold Rating

Biomea Fusion (NASDAQ:BMEA) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Other analysts have also issued reports about the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biomea Fusion in a research note on Wednesday, January 21st. Citigroup increased their price objective on Biomea Fusion from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Friday. D. Boral Capital restated a “buy” rating and issued a $12.00 price objective on shares of Biomea Fusion in a report on Wednesday. Finally, Rodman & Renshaw began coverage on shares of Biomea Fusion in a research note on Tuesday, January 13th. They set a “buy” rating and a $8.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.75.

Biomea Fusion Trading Down 3.6%

BMEA stock opened at $1.32 on Friday. Biomea Fusion has a 12-month low of $0.87 and a 12-month high of $3.08. The business’s 50-day moving average is $1.29 and its 200 day moving average is $1.42. The stock has a market cap of $95.44 million, a price-to-earnings ratio of -1.01 and a beta of -0.20.

Institutional Investors Weigh In On Biomea Fusion

A number of large investors have recently made changes to their positions in BMEA. AQR Capital Management LLC increased its holdings in shares of Biomea Fusion by 670.5% in the first quarter. AQR Capital Management LLC now owns 264,028 shares of the company’s stock valued at $562,000 after purchasing an additional 229,763 shares during the last quarter. XTX Topco Ltd acquired a new stake in Biomea Fusion during the second quarter worth about $270,000. Scotia Capital Inc. acquired a new stake in Biomea Fusion during the second quarter worth about $459,000. Aisling Capital Management LP raised its stake in Biomea Fusion by 156.5% during the second quarter. Aisling Capital Management LP now owns 2,048,757 shares of the company’s stock worth $3,688,000 after purchasing an additional 1,250,000 shares during the period. Finally, Bridgeway Capital Management LLC raised its stake in Biomea Fusion by 99.2% during the second quarter. Bridgeway Capital Management LLC now owns 70,300 shares of the company’s stock worth $127,000 after purchasing an additional 35,000 shares during the period. 96.72% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Biomea Fusion

Here are the key news stories impacting Biomea Fusion this week:

• Positive Sentiment: Citigroup raised its price target on BMEA from $6.00 to $7.00 and reiterated a “buy” rating — the new target implies substantial upside versus the current share level. Read More.
• Positive Sentiment: HC Wainwright published a set of updated EPS forecasts (Q1–Q4 2026 and FY2026–FY2028) and materially lifted its multi-year loss estimates (FY2026 from ($1.37) to ($0.57); FY2027 to ($0.64); FY2028 to ($0.78)), signaling the firm expects smaller losses and improving financials over time. The report also lists per-quarter EPS expectations for 2026. Read More.
• Positive Sentiment: D. Boral Capital initiated/maintained a buy rating on Biomea Fusion, adding another independent positive analyst voice. Read More.
• Positive Sentiment: Recent coverage highlights continued strong analyst sentiment driven by encouraging diabetes trial results, supporting the investment case for BMEA’s pipeline upside. Read More.
• Neutral Sentiment: Despite the positive analyst action and trial commentary, the stock is trading lower today — likely a short-term reaction (profit-taking, low liquidity, or risk-off flows common in small-cap biotech) rather than a reversal of analyst views. Monitor trading volume and upcoming clinical or corporate catalysts for signs of follow-through.

About Biomea Fusion

Biomea Fusion, Inc (NASDAQ:BMEA) is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors.

The company’s lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction.